US 12,479,898 B2
Pharmaceutical composition comprising immunoglobulin fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases
Moon Cheol Kang, Pohang-si (KR); Young Woo Choi, Pohang-si (KR); Donghoon Choi, Yongin-si (KR); and Young Chul Sung, Seoul (KR)
Assigned to GENEXINE, INC., Seongnam-si (KR)
Filed by GENEXINE, INC., Seongnam-si (KR)
Filed on Jun. 1, 2023, as Appl. No. 18/327,423.
Application 18/327,423 is a continuation of application No. 15/775,182, granted, now 11,708,399, previously published as PCT/KR2016/014127, filed on Dec. 2, 2016.
Claims priority of provisional application 62/361,170, filed on Jul. 12, 2016.
Claims priority of provisional application 62/360,696, filed on Jul. 11, 2016.
Claims priority of provisional application 62/263,262, filed on Dec. 4, 2015.
Prior Publication US 2024/0018205 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/54 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 38/20 (2006.01); A61K 47/02 (2006.01); A61P 35/00 (2006.01)
CPC C07K 14/5418 (2013.01) [A61K 9/0034 (2013.01); A61K 9/08 (2013.01); A61K 38/2046 (2013.01); A61K 47/02 (2013.01); A61P 35/00 (2018.01); C07K 2319/30 (2013.01)] 18 Claims
 
1. A pharmaceutical composition comprising an interleukin-7 (IL-7) fusion protein, wherein the IL-7 fusion protein comprises an IL-7 protein, an immunoglobulin Fc region, and an oligopeptide;
wherein the IL-7 protein comprises: (a) amino acid residues 26-177 of the amino acid sequence set forth in SEQ ID NO: 1; (b) amino acid residues 26-154 of the amino acid sequence set forth in SEQ ID NO: 2; (c) amino acid residues 26-154 of the amino acid sequence set forth in SEQ ID NO: 3; (d) amino acid residues 26-177 of the amino acid sequence set forth in SEQ ID NO: 4; (e) amino acid residues 26-176 of the amino acid sequence set forth in SEQ ID NO: 5; or (f) amino acid residues 26-178 of the amino acid sequence set forth in SEQ ID NO: 6;
wherein the immunoglobulin Fc region comprises the amino acid sequence set forth in any one of SEQ ID NOs: 9 to 14; and
wherein the oligopeptide is selected from the group consisting of methionine, glycine, methionine-methionine, glycine-glycine, methionine-glycine, glycine-methionine, methionine-methionine-methionine, methionine-methionine-glycine, methionine-glycine-methionine, glycine-methionine-methionine, methionine-glycine-glycine, glycine-methionine-glycine, glycine-glycine-methionine, methionine-methionine-methionine, and glycine-glycine-glycine.